Internationalisation
The company expanded abroad, setting up both production facilities and commercial operations. They opened the first production plant in Brazil in 1956 under the name Zambon Laboratorios Farmaceuticos SA, which was changed to Ltda in 1993.
Zambon SA was established in Barcelona, Spain, in 1960 to serve the Iberian Peninsula (an independent Portuguese headquarters was opened in Lisbon, in 1992). The main brand of Zambon on the Spanish market is Ultra Levura, a probiotic treatment.
In 1961, Alberto Zambon moved the main headquarters and research laboratories to Bresso, Milan, while the production facility remained in Vicenza.
In 1963, Inpharzam was founded in Lamone, Switzerland, which served as a holding group for all the international businesses. This branch later moved to Cadempino, where a specialist pharmaceutical production plant was established. Davizam SA, Siphar and the Inpharzam Trading Company SA were also established in Lugano.
Founded in the same year, Zambon France focused on sales and exports to Africa and Australia.
Fluimicil went on the market in 1965. During this period, the company started to build relationships in Japan through a collaboration with EISAI, which produced injectable chloramphenicol in Japan.
A new chemical ingredients plant was built in Almisano di Lonigo in 1970.
In 1975, Zambon Colombia SA was established with headquarters in Bogota.
In 1980, Inpharzam International established relationships with various companies, including Carlo Erba.
In 1983, Zambon bought out Emilio Ghirardi’s company Simes and production was moved to a new plant in Vicenza in 1984. That same year, Zambon B.V. was founded with headquarters in Amsterdam and Zambon Nederland BV was established.
A year later, Alberto Zambon was appointed a Knight of the Order of Merit for Labour, exactly 50 years after his father’s nomination.
1989 saw the founding of both Zambon UK and Zambon Corporation for the American market.
In 1996, the Shantou Shanning Zambon Chemicals Ltd (Equity Joint Venture) was founded and its plant was opened a year later.
In Europe, Inpharzam SA was established in Belgium in 1995.
In 2000, a second Chinese plant was opened in Hainan, dividing chemical and pharmaceutical production between Shantou and Hainan. In 2002 Zambon India was established and Zambon Indonesia two years later.
The group invested in the respiratory field, especially in the treatment of severe diseases such as chronic obstructive pulmonary disease and rare illnesses, and in June 2013, Zambon acquired Profile Pharma in the United Kingdom, which specialised in cystic fibrosis. At the same time, Zambon entered the central nervous system therapy area with the molecule safinamide.
